Fusion Antibodies (LON:FAB) Stock Price Down 11.3% – What’s Next?

Fusion Antibodies plc (LON:FAB) was down 11.3% during trading on Thursday . The stock traded as low as GBX 4.33 ($0.06) and last traded at GBX 4.35 ($0.06). Approximately 954,842 shares changed hands during trading, a decline of 14% from the average daily volume of 1,116,575 shares. The stock had previously closed at GBX 4.90 ($0.06).

Fusion Antibodies Stock Performance

The company has a debt-to-equity ratio of 2.40, a quick ratio of 2.36 and a current ratio of 3.87. The stock has a market cap of £4.01 million, a P/E ratio of -105.00 and a beta of 0.49. The firm’s 50 day moving average is GBX 3.69 and its 200 day moving average is GBX 3.53.

Insider Buying and Selling

In other news, insider Adrian Kinkaid acquired 120,000 shares of Fusion Antibodies stock in a transaction that occurred on Wednesday, September 4th. The stock was purchased at an average price of GBX 3 ($0.04) per share, for a total transaction of £3,600 ($4,700.97). In related news, insider Adrian Kinkaid purchased 120,000 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were acquired at an average price of GBX 3 ($0.04) per share, for a total transaction of £3,600 ($4,700.97). Also, insider Simon Gordon Douglas purchased 150,000 shares of the business’s stock in a transaction on Monday, July 22nd. The shares were bought at an average price of GBX 3 ($0.04) per share, for a total transaction of £4,500 ($5,876.21). Insiders bought a total of 448,553 shares of company stock worth $1,429,387 in the last 90 days. 11.39% of the stock is owned by corporate insiders.

About Fusion Antibodies

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services.